MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 17.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 76,534 shares of the company's stock after acquiring an additional 11,223 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.06% of Vaxcyte worth $6,266,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in PCVX. Lazard Asset Management LLC acquired a new position in Vaxcyte during the 4th quarter valued at about $39,846,000. LMR Partners LLP lifted its holdings in Vaxcyte by 129.5% in the fourth quarter. LMR Partners LLP now owns 5,600 shares of the company's stock valued at $458,000 after buying an additional 24,600 shares during the period. Hudson Bay Capital Management LP bought a new position in Vaxcyte in the fourth quarter valued at approximately $8,083,000. Ethic Inc. acquired a new stake in Vaxcyte during the 4th quarter worth $462,000. Finally, Ensign Peak Advisors Inc lifted its stake in shares of Vaxcyte by 7.2% in the 4th quarter. Ensign Peak Advisors Inc now owns 586,128 shares of the company's stock valued at $47,980,000 after purchasing an additional 39,293 shares during the period. Institutional investors own 96.78% of the company's stock.
Insiders Place Their Bets
In related news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the sale, the chief operating officer now owns 154,931 shares of the company's stock, valued at approximately $11,351,794.37. The trade was a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.10% of the company's stock.
Analyst Ratings Changes
A number of research firms recently commented on PCVX. The Goldman Sachs Group dropped their price objective on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Guggenheim reaffirmed a "buy" rating and issued a $160.00 price target on shares of Vaxcyte in a research note on Wednesday, March 12th. Bank of America reduced their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a research note on Tuesday, April 8th. Finally, Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Vaxcyte has a consensus rating of "Buy" and a consensus target price of $136.50.
Check Out Our Latest Report on Vaxcyte
Vaxcyte Stock Performance
NASDAQ PCVX traded up $4.54 on Tuesday, reaching $36.57. The company had a trading volume of 4,372,071 shares, compared to its average volume of 1,353,918. The company's fifty day moving average is $41.01 and its 200-day moving average is $70.70. The firm has a market capitalization of $4.72 billion, a price-to-earnings ratio of -7.95 and a beta of 1.27. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the prior year, the business earned ($0.85) earnings per share. On average, research analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.
About Vaxcyte
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Read More
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
